World
Kalshi and Polymarket face criticism over clinical trial betting
Researchers criticize the practice of betting on clinical trials by platforms like Kalshi and Polymarket as potentially harmful to drug development. The companies defend their services, arguing they provide valuable information.
Coverage timeline — 1 article
NPR
Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
2026-08-07 10:00 UTC